Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.41 |
| ▸ | BCHE | P06276 | 7/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | CCR4 | P51679 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL775697 | 0.99 | ACHE (0.42) | ACHEBCHEIRAK4EGFRSRC | |
| SCHEMBL773574 | 0.78 | TP53 (0.44) | IRAK4CCR4HPGDSMAPT | |
| SCHEMBL775966 | 0.77 | TP53 (0.45) | IRAK4HPGDSMAPT | |
| SCHEMBL775253 | 0.76 | CYP1A2 (0.46) | EGFRMAPT | |
| SCHEMBL773566 | 0.76 | CYP1A2 (0.46) | EGFRMAPT | |
| SCHEMBL23261082 | 0.73 | TP53 (0.60) | MAPT | |
| SCHEMBL30764405 | 0.73 | TP53 (0.60) | MAPT | |
| SCHEMBL774356 | 0.70 | TNF (0.45) | — | |
| SCHEMBL774769 | 0.69 | TNF (0.46) | — | |
| SCHEMBL1401187 | 0.69 | PDGFRB (0.70) | EGFRCCR4HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071505-A1 | SUBSTITUTED PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE TO TREAT OXIDATIVE STRESS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2011022216-A1 | SUBSTITUTED PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE TO TREAT OXIDATIVE STRESS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071505-A1 | SUBSTITUTED PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE TO TREAT OXIDATIVE STRESS | HMOX2, HMOX1, MPO | ACHE 722/4885BCHE 1557/4885IRAK4 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.